[Form 4] The Beauty Health Company Insider Trading Activity

Rhea-AI Filing Summary

Form 4 filing for The Beauty Health Company (SKIN) discloses that director Michelle C. Kerrick was granted 73,051 restricted stock units (RSUs) on 06/16/2025 (Transaction Code A).

• The RSUs vest on the earlier of the one-year anniversary of the grant or the date of the company’s 2026 annual shareholders’ meeting, subject to her continued board service.
• After the grant, Kerrick’s total beneficial ownership increases to 189,813 Class A shares, held directly.
• No derivative securities were involved and no shares were sold.

The filing represents routine director equity compensation and does not indicate any open-market buying or selling activity.

Insights

Corporate Governance Analyst

TL;DR: Routine RSU grant aligns director with shareholders; negligible impact on valuation.

The 73,051-share RSU award is standard annual compensation for outside directors. It marginally dilutes existing holders but strengthens incentive alignment by tying the director’s wealth to share performance through a one-year vesting schedule. The increase brings Kerrick’s stake to roughly 0.1% of the 181 million shares outstanding—immaterial from a market-moving perspective. No cash changed hands, and there is no signal of insider conviction through open-market purchases or sales. Overall, the disclosure is governance-neutral and unlikely to influence the stock’s risk/reward profile.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kerrick Michelle C.

(Last) (First) (Middle)

C/O THE BEAUTY HEALTH COMPANY

2165 SPRING STREET

(Street)

LONG BEACH CA 90806

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beauty Health Co [ SKIN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/16/2025		A(1)		73,051	A(1)	(1)	189,813	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units ("RSUs"). The RSUs vest on the earlier of the one-year anniversary of the grant and the date of the 2026 Annual Meeting of Stockholders of the Company, contingent upon the reporting person's continued service as a member of the Company's board of directors through such time.

Remarks:

	/s/ Michelle C. Kerrick	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many SKIN shares did Director Michelle C. Kerrick receive?

She received 73,051 restricted stock units on 06/16/2025.

When will the newly granted RSUs to Kerrick vest?

The RSUs vest on the earlier of one year from grant or the 2026 annual shareholder meeting, provided she remains on the board.

What is Kerrick’s total beneficial ownership after the transaction?

Her ownership increases to 189,813 Class A shares of The Beauty Health Company.

Did the Form 4 include any insider sales of SKIN stock?

No. The filing only reports an acquisition of RSUs; no shares were sold.

Does this RSU grant materially dilute existing shareholders?

The grant represents about 0.04% of outstanding shares, a negligible level of dilution.